News
SNY
48.25
+0.08%
0.04
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
A small group of European stocks has quietly outperformed most of the world. Goldman Sachs dubbed the group "Granolas" and it accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. Granolas refers to a group of 11 European stocks operating in the healthcare and pharmaceutical sector. The group also includes luxury, consumer staples and software technology companies.
Benzinga · 49m ago
Validea James P. O'Shaughnessy Strategy Daily Upgrade Report - 2/28/2024
NASDAQ · 9h ago
‘Tripledemic’ burden lower this winter despite COVID impact: Airfinity
Seeking Alpha · 1d ago
Peru To Declare Emergency In Parts Of Country For Increase In Dengue Cases
Benzinga · 2d ago
Weekly Report: what happened at SNY last week (0219-0223)?
Weekly Report · 2d ago
Reported Saturday, Sanofi's Rilzabrutinib Phase 2 Results Demonstrate Rapidly Reduced Itch Severity And Significantly Improved Disease Activity In Adults With Chronic Spontaneous Urticaria
Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria. The oral BTK inhibitor is one of 12 potential blockbusters in Sanofi's leading immunology pipeline.
Benzinga · 2d ago
Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)
Seeking Alpha · 2d ago
BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales
NASDAQ · 5d ago
Sanofi, Regeneron win FDA priority review for Dupixent label expansion
Healthcare Sanofi, Regeneron win FDA priority review for Dupixent label expansion. The drug is an anti-inflammatory medication used for allergic diseases. The FDA will review the drug in a sixth potential indication in certain adult patients with chronic obstructive pulmonary disease. If approved, it would be the only biologic therapy for COPD.
Seeking Alpha · 5d ago
Regeneron Pharmaceuticals And Sanofi Announce That Dupixent® sBLA Has Been Accepted For FDA Priority Review For Treatment of COPD With Type 2 Inflammation
Priority Review granted based on positive results from two Phase 3 trials. Dupixent would be the only biologic therapy for COPD and the first new treatment approach for the disease in more than a decade. It is the leading biologic treatment for all five of its FDA-approved indications in the U.S.
Benzinga · 5d ago
Sanofi: Dupixent SBLA Accepted For FDA Priority Review For COPD With Type 2 Inflammation
NASDAQ · 5d ago
Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy
Seeking Alpha · 5d ago
Top Analyst Reports for Microsoft, Amazon.com & Berkshire Hathaway
NASDAQ · 5d ago
More
Webull provides a variety of real-time SNY stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About SNY
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.